Show simple item record

dc.contributor.advisorŞanli Mohamed, Gülşahen
dc.contributor.authorTuran, Taylanen
dc.date.accessioned2014-07-22T13:51:02Z
dc.date.available2014-07-22T13:51:02Z
dc.date.issued2011en
dc.identifier.urihttp://hdl.handle.net/11147/3182
dc.descriptionThesis (Master)--İzmir Institute of Technology, Chemistry, İzmir, 2011en
dc.descriptionIncludes bibliographical references (leaves: 89-101)en
dc.descriptionText in English; Abstract: Turkish and Englishen
dc.descriptionxi, 111 leavesen
dc.description.abstractMultiple Myeloma is a malignant B-cell neoplasm that is characterized by the accumulation of malignant plasma cells in the bone marrow. Over the recent years, several novel agents have been introduced in the treatment of this disease. Bortezomib is the first of a new class of agents known as proteasome inhibitors. The main objective of the project was basically to both determine the cytotoxic and apoptotic effects of Bortezomib on Multiple Myeloma U-266 cells and compare and explore the differences between Bortezomib applied Multiple Myeloma cells and control group Multiple Myeloma cells, by proteomics studies. In order to achieve our aims in the project, variety of multidisciplinary subjects were come together. Cancer research techniques, biochemical studies at protein level and proteomics were combined in our studies. In this study, our experimental results demonstrated that Bortezomib has antiproliferative and apoptotic effects on MM U-266 cells. On the other hand, the responsible proteins for the effect mechanism of anti-cancer agent on cells were determined by MALDI-TOF-TOF Mass Spectrometry for the first time. According to the mass spectrometric analysis, 37 protein spots were differentially expressed. Among them, five proteins were newly formed, ten proteins lost, twelve proteins were up-regulated and ten proteins were down-regulated as compared to control group (untreated cells).These differential expressed proteins in response to Bortezomib have different important functions ranging from cell signaling transduction, cell cycle regulation, apoptosis to immunity and defense mechanism. In conclusion, it was identified which proteins have a central role behind the effect of Bortezomib on MM U-266 cells. The identified proteins may let to be possible to treat other cancer types by same anticancer agent. The data obtained by this study may also be helpful for medical schools and drug designers and may also provide new treatments.en
dc.language.isoengen
dc.publisherİzmir Institute of Technologyen
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject.lcshMultiple myelomaen
dc.subject.lcshTime-of-flight mass spectrometryen
dc.subject.lcshAntineoplastic agentsen
dc.subject.lcshProteomicsen
dc.titleChanges in protein profiles in Bortezomib applied Multiple Myeloma cellsen
dc.typemasterThesisen
dc.contributor.departmentİzmir Institute of Technology. Chemistryen
dc.relation.publicationcategoryTezen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record